Lack of efficacy of infliximab in the treatment of primary sclerosing cholangitis in inflammatory bowel diseases in childhood

Eur J Gastroenterol Hepatol. 2017 Jun;29(6):736. doi: 10.1097/MEG.0000000000000847.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Cholangitis, Sclerosing / diagnosis
  • Cholangitis, Sclerosing / drug therapy*
  • Cholangitis, Sclerosing / immunology
  • Colitis, Ulcerative / diagnosis
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / immunology
  • Female
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Infliximab / adverse effects
  • Infliximab / therapeutic use*
  • Male
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Gastrointestinal Agents
  • Infliximab

Supplementary concepts

  • Pediatric ulcerative colitis